Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AVXL logo AVXL
Upturn stock ratingUpturn stock rating
AVXL logo

Anavex Life Sciences Corp (AVXL)

Upturn stock ratingUpturn stock rating
$9.22
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: AVXL (5-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Outstanding Performance

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $34.33

1 Year Target Price $34.33

Analysts Price Target For last 52 week
$34.33 Target price
52w Low $4.93
Current$9.22
52w High $14.44

Analysis of Past Performance

Type Stock
Historic Profit 62.63%
Avg. Invested days 25
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 828.02M USD
Price to earnings Ratio -
1Y Target Price 34.33
Price to earnings Ratio -
1Y Target Price 34.33
Volume (30-day avg) 3
Beta 0.8
52 Weeks Range 4.93 - 14.44
Updated Date 08/29/2025
52 Weeks Range 4.93 - 14.44
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.57

Earnings Date

Report Date 2025-08-12
When -
Estimate -0.1457
Actual -0.16

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -27.41%
Return on Equity (TTM) -43.64%

Valuation

Trailing PE -
Forward PE 3.89
Enterprise Value 690777149
Price to Sales(TTM) -
Enterprise Value 690777149
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -5.54
Shares Outstanding 85893800
Shares Floating 83048171
Shares Outstanding 85893800
Shares Floating 83048171
Percent Insiders 3.31
Percent Institutions 38.32

ai summary icon Upturn AI SWOT

Anavex Life Sciences Corp

stock logo

Company Overview

overview logo History and Background

Anavex Life Sciences Corp. was founded in 2004. It is a biopharmaceutical company focused on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system (CNS) disorders.

business area logo Core Business Areas

  • Drug Development: Research and development of novel drug candidates targeting neurodegenerative and neurodevelopmental diseases.
  • Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of drug candidates.
  • Commercialization: Seeking regulatory approval and commercializing approved products.

leadership logo Leadership and Structure

Christopher U Missling, PhD (President and CEO). The company operates with a research and development-focused organizational structure, with departments dedicated to preclinical research, clinical development, regulatory affairs, and business development.

Top Products and Market Share

overview logo Key Offerings

  • ANAVEXu00ae2-73 (blarcamesine): An investigational drug candidate for the treatment of Alzheimer's disease, Parkinson's disease, Rett syndrome, and other CNS disorders. Currently in clinical trials. Market share is pending regulatory approval and commercialization. Competitors include companies developing Alzheimer's and Parkinson's disease therapeutics, such as Biogen (BIIB), Eli Lilly (LLY), and Roche (RHHBY).
  • ANAVEXu00ae3-71: An investigational drug candidate for the treatment of neurodegenerative diseases. Currently in preclinical and early clinical development. Market share is pending regulatory approval and commercialization. Competitors include companies developing Alzheimer's therapeutics.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry focused on neurodegenerative diseases is highly competitive and rapidly evolving, with a significant unmet need for effective treatments.

Positioning

Anavex Life Sciences Corp. is a smaller player in the pharmaceutical market, primarily focused on the sigma-1 receptor, and is developing drug candidates with potential disease-modifying effects. This is a more novel and risky approach as opposed to the symptomatic treatments that the big players focus on.

Total Addressable Market (TAM)

The TAM for Alzheimer's and Parkinson's disease therapeutics is estimated to be tens of billions of dollars annually. Anavex is positioned to potentially capture a share of this market if its drug candidates are approved.

Upturn SWOT Analysis

Strengths

  • Novel drug candidates with potential disease-modifying effects
  • Strong intellectual property portfolio
  • Experienced management team
  • Sigma-1 receptor focus which other companies are not focusing on

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • High risk of clinical trial failure
  • Dependence on successful development and commercialization of drug candidates
  • Small team

Opportunities

  • Partnerships and collaborations with larger pharmaceutical companies
  • Expansion of pipeline through acquisition or in-licensing of new drug candidates
  • Regulatory approval and commercialization of drug candidates
  • Breakthrough Therapy designation from FDA

Threats

  • Clinical trial failures
  • Competition from other companies developing treatments for neurodegenerative diseases
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • BIIB
  • LLY
  • RHHBY
  • ABBV

Competitive Landscape

Anavex is smaller than its main competitors. ANAVEXu00ae2-73 offers a unique mechanism and may be superior in the long term if proven through data during clinical trials and is able to navigate regulatory approval.

Growth Trajectory and Initiatives

Historical Growth: Historically, growth has been driven by advancements in clinical trials and securing financing.

Future Projections: Future growth is contingent on the successful completion of clinical trials and regulatory approval of drug candidates. Analyst estimates are highly variable and depend on trial outcomes.

Recent Initiatives: Advancing clinical trials for ANAVEXu00ae2-73 in Alzheimer's disease, Parkinson's disease, and Rett syndrome. Exploring new indications for drug candidates.

Summary

Anavex Life Sciences Corp. is a high-risk, high-reward biopharmaceutical company. While the company's novel approach offers significant potential, it faces challenges related to funding, clinical trial success, and regulatory approval. Positive clinical trial outcomes for ANAVEXu00ae2-73 could lead to substantial value creation, but negative results could significantly impact the company's prospects. They need to secure more funding and continue to push for regulatory approval. The success of trials and regulatory approval are the main aspects to look out for.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Press releases
  • Analyst reports
  • Industry reports

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investing in biopharmaceutical companies carries significant risk. Market share data is estimated and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Anavex Life Sciences Corp

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2006-08-02
President, CEO, Secretary & Director Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 42
Full time employees 42

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.